查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1462605

2030年癌症支持治療藥物的市場預測：按癌症類型、支持治療類型、藥物類型、給藥方法、分銷管道和地區進行全球分析

Cancer Supportive Care Drugs Market Forecasts to 2030 - Global Analysis By Cancer Type, Supportive Care Type, Drug Type, Mode of Administration, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球癌症支持治療藥物市場規模為 214.6 億美元，預計到 2030 年將達到 265.7 億美元，預測期內年複合成長率為 2.4%。

癌症支持治療藥物是一種旨在控制癌症治療的症狀和副作用的藥物，目的是改善患者的生活品質。這些藥物針對化療、放射線治療和其他癌症治療引起的各種問題，例如疼痛、噁心、疲勞和免疫抑制。這些藥物包括止痛藥、止吐藥、造血生長因子和發炎藥物。這些藥物還可以透過減少不適和增加您的整體幸福感來幫助維持治療順從性。

根據美國國家癌症研究所的SEER資料庫，2020年，未來20年癌症新病例數預計將達到2,840萬例。

全球癌症盛行率不斷上升

隨著越來越多的人被診斷出患有癌症，對支持性護理藥物來控制與癌症治療相關的症狀和副作用的需求不斷成長。這種需求的增加源於緩解疼痛、噁心、疲勞和其他治療相關併發症以及改善患者生活品質的需要。因此，製藥公司渴望開發支持性護理藥物並進行創新，推動市場開拓，以滿足全球癌症患者日益成長的醫療需求。

副作用和毒性

癌症支持治療藥物的副作用包括噁心、嘔吐、疲勞、貧血、神經病變和免疫抑制。此外，有些藥物可能對肝臟和腎臟等器官有毒。這些副作用和毒性可能導致治療中斷、減重或停止，影響患者的依從性和治療結果。此外，對副作用的擔憂可能會阻止醫療保健專業人員開立某些藥物，從而可能影響市場需求。

擴大安寧療護服務

安寧療護的整合強調了控制疼痛、噁心和其他副作用的重要性，並促進了支持性護理藥物的開發和採用。安寧療護服務的擴大將增加對緩解症狀和改善癌症患者生活品質的藥物的需求。這種擴張不僅改善了患者的福祉，而且還創造了一個環境，​​使製藥公司可以創新並推出新的治療方法滿足接受癌症治療的患者的獨特需求，從而刺激市場成長。

醫療基礎設施不足

設施、訓練有素的人員和資源不足會導致診斷、治療開始和癌症相關症狀的適當管理的延遲。此外，基礎設施薄弱往往會導致醫療保健服務的差異，對服務不足的人口造成不成比例的影響。如果沒有足夠的基礎設施來支持全面的癌症治療，對支持性護理藥物的需求將無法得到滿足，從而阻礙市場擴張並阻止患者接受基本治療以緩解症狀和改善生活品質。

COVID-19 的影響

COVID-19 的爆發對癌症支持治療藥物市場產生了重大影響。癌症篩檢、診斷和治療的延誤以及醫療保健服務的中斷正在影響對支持性護理藥物的需求。此外，供應鏈中斷和應對疫情的資源重新分配進一步加劇了市場動態的緊張。總體而言，這場大流行強調了有彈性的醫療保健系統的重要性，並強調了在提供癌症護理方面採用創新方法的必要性。

前列腺癌領域預計在預測期內規模最大

前列腺癌領域預計將出現良好的成長。在支持性癌症醫學領域，應對攝護腺癌的挑戰需要採取多方面的方法。前列腺癌的支持性治療藥物旨在減少治療的副作用並提高患者的生活品質。此外，針對攝護腺癌特有症狀和併發症（例如泌尿功能障礙和勃起功能障礙）的藥物也可能發揮重要作用。這些藥物的開發和供應對於增強前列腺癌患者的整體護理和福祉至關重要。

靜脈注射藥物領域預計在預測期內年複合成長率最高。

預計靜脈注射藥物細分市場在預測期內將以最高的年複合成長率成長。靜脈注射藥物透過將藥物直接輸送到血液中，確保快速有效的吸收，在支持性癌症治療中發揮至關重要的作用。這些藥物對於控制化療引起的副作用（如噁心、嘔吐、貧血、嗜中性白血球低下和疼痛）至關重要。這些藥物提供有針對性的治療，可以精確劑量和即時緩解，改善接受治療的癌症患者的生活品質。

比最大的地區

預計亞太地區在預測期內將佔據最大的市場佔有率。癌症發生率正在增加，特別是在中國和印度等人口大國，這增加了對支持性護理藥物來控制癌症治療的症狀和副作用的需求。此外，醫療基礎設施的改善和癌症治療意識的提高也有助於市場擴張。此外，製藥公司和醫療機構之間的合作以及政府加強癌症護理服務的舉措正在進一步推動癌症支持治療藥物市場的成長。

年複合成長率最高的地區：

預計北美在預測期內的年複合成長率最高。高癌症發生率、先進的醫療基礎設施以及對研發的重視等因素促成了這一成長。此外，有利的報銷政策以及患者和醫療保健專業人員意識的提高正在推動對支持性護理藥物的需求。北美專注於改善患者的治療結果和生活品質，仍然是支持性癌症治療藥物開發和商業化的重要地區。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次研究資料
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • COVID-19 疾病的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球癌症支持治療藥物市場：依癌症類型分類

  • 乳癌
  • 肺癌
  • 攝護腺癌
  • 大腸直腸癌
  • 其他癌症類型

第6章全球癌症支持治療藥物市場：依支持治療類型

  • 化療引起的噁心和嘔吐（CINV）的治療
  • 貧血管理
  • 嗜中性白血球低下症的治療
  • 骨轉移的治療
  • 疼痛管理
  • 疲勞管理
  • 其他支持性護理類型

第7章全球癌症支持治療藥物市場：依藥物類型

  • 止吐藥
  • 紅血球生成刺激因子 (ESA)
  • 顆粒細胞增生因子(G-CSF)
  • 雙磷酸鹽
  • 非類固醇消炎劑(NSAID)
  • 皮質類固醇
  • 其他藥物種類

第8章全球癌症支持治療藥物市場：依給藥方法分類

  • 口腔醫學
  • 注射藥物
  • 外用藥
  • 靜脈注射藥物
  • 其他管理方法

第9章全球癌症支持治療藥物市場：按分銷管道

  • 醫院藥房
  • 零售藥房
  • 網路藥房
  • 癌症治療中心
  • 其他分銷管道

第10章全球癌症支持治療藥物市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Amgen Inc.
  • Johnson & Johnson
  • Pfizer Inc.
  • Novartis International AG
  • Merck & Co. Inc.
  • Teva Pharmaceutical Industries Limited
  • F. Hoffmann-La Roche Limited
  • Bayer AG
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Bristol Myers Squibb
  • GlaxoSmithKline PLC
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.
  • Daiichi Sankyo Company
Product Code: SMRC25656

According to Stratistics MRC, the Global Cancer Supportive Care Drugs Market is accounted for $21.46 billion in 2023 and is expected to reach $26.57 billion by 2030 growing at a CAGR of 2.4% during the forecast period. Cancer supportive care drugs are medications designed to manage the symptoms and side effects of cancer treatment, aiming to improve patients' quality of life. These drugs target various issues such as pain, nausea, fatigue, and immune suppression caused by chemotherapy, radiation therapy, or other cancer treatments. They include analgesics, antiemetics, hematopoietic growth factors, and anti-inflammatory agents. These drugs also assist in maintaining treatment adherence by reducing discomfort and enhancing overall well-being.

According to the SEER Database of the U.S. National Cancer Institute, 2020, in the next twenty years, there will likely be 28.4 million new instances of cancer.

Market Dynamics:

Driver:

Rising prevalence of cancer globally

With an increasing number of individuals diagnosed with cancer, there is a higher demand for supportive care drugs to manage symptoms and side effects associated with cancer treatments. This increased demand stems from the necessity to alleviate pain, nausea, fatigue, and other treatment-related complications, enhancing patients' quality of life. Consequently, pharmaceutical companies are motivated to develop and innovate supportive care drugs, driving market expansion to meet the growing healthcare needs of cancer patients worldwide.

Restraint:

Side effects and toxicity

Side effects of cancer supportive care drugs can include nausea, vomiting, fatigue, anaemia, neuropathy, and immunosuppression. Additionally, some drugs may pose risks of toxicity to organs such as the liver or kidneys. These side effects and toxicities can lead to treatment interruptions, dose reductions, or discontinuation, affecting patient adherence and treatment outcomes. Moreover, concerns about adverse effects may deter healthcare providers from prescribing certain drugs, impacting market demand.

Opportunity:

Expansion of palliative care services

Palliative care integration underscores the importance of managing pain, nausea, and other side effects, prompting the development and adoption of supportive care drugs. Expansion of palliative care services increases the demand for medications that alleviate symptoms and improve quality of life for cancer patients. This expansion not only enhances patient well-being but also creates a conducive environment for pharmaceutical companies to innovate and introduce new therapies tailored to address the unique needs of individuals undergoing cancer treatment, thereby fueling market growth.

Threat:

Inadequate healthcare infrastructure

Insufficient facilities, trained personnel, and resources lead to delays in diagnosis, treatment initiation, and proper management of cancer-related symptoms. Moreover, poor infrastructure often results in disparities in healthcare delivery, disproportionately affecting underserved populations. Without adequate infrastructure to support comprehensive cancer care, the demand for supportive care drugs remains unmet, hindering market expansion and depriving patients of essential treatments to alleviate symptoms and improve quality of life.

Covid-19 Impact

The covid-19 pandemic has significantly impacted the cancer supportive care drugs market. Delays in cancer screenings, diagnosis, and treatment, alongside disruptions in healthcare services, have affected the demand for supportive care drugs. Additionally, supply chain disruptions and resource reallocation to address the pandemic have further strained market dynamics. Overall, the pandemic has underscored the importance of resilient healthcare systems and highlighted the need for innovative approaches to cancer care delivery.

The prostate cancer segment is expected to be the largest during the forecast period

The prostate cancer segment is estimated to have a lucrative growth. In the realm of cancer supportive care drugs, addressing the challenges of prostate cancer entails a multifaceted approach. Supportive care drugs for prostate cancer aim to mitigate treatment side effects and improve patients' quality of life. Additionally, drugs targeting prostate cancer-specific symptoms and complications, such as urinary issues or erectile dysfunction, may also play a crucial role. The development and availability of these drugs are pivotal in enhancing the holistic care and well-being of prostate cancer patients.

The intravenous drugs segment is expected to have the highest CAGR during the forecast period

The intravenous drugs segment is anticipated to witness the highest CAGR growth during the forecast period. Intravenous drugs play a pivotal role in cancer supportive care by delivering medications directly into the bloodstream, ensuring rapid and efficient absorption. These drugs are crucial for managing chemotherapy-induced side effects such as nausea, vomiting, anaemia, neutropenia, and pain. They offer targeted treatment, allowing for precise dosing and immediate relief, thereby enhancing the quality of life for cancer patients undergoing treatment.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. Increasing cancer prevalence, particularly in populous countries like China and India, drives demand for supportive care drugs to manage symptoms and side effects of cancer treatment. Additionally, improving healthcare infrastructure and rising awareness about cancer care contribute to market expansion. Moreover, collaborations between pharmaceutical companies and healthcare organizations, along with government initiatives to enhance cancer care services, further propel the growth of the cancer supportive care drugs market.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period. Factors such as a high prevalence of cancer, advanced healthcare infrastructure, and strong emphasis on research and development contribute to this growth. Moreover, favourable reimbursement policies and increasing awareness among both patients and healthcare providers drive demand for supportive care drugs. With a focus on improving patient outcomes and quality of life, North America remains a key region for the development and commercialization of cancer supportive care drugs.

Key players in the market

Some of the key players profiled in the Cancer Supportive Care Drugs Market include Amgen Inc., Johnson & Johnson, Pfizer Inc., Novartis International AG, Merck & Co. Inc., Teva Pharmaceutical Industries Limited, F. Hoffmann-La Roche Limited, Bayer AG, Eli Lilly and Company, AstraZeneca PLC, Bristol Myers Squibb, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, AbbVie Inc. and Daiichi Sankyo Company.

Key Developments:

In November 2023, AstraZeneca's Truqap in combination with Faslodex has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations. Eligible patients will have progressed on at least one endocrine-based regimen in the metastatic setting or experienced recurrence on or within 12 months of completing adjuvant therapy.

In March 2022, Novartis received approval from the United States Food and Administration (FDA) for Pluvicto, developed for the treatment of adult patients with prostate cancer. The cancer supportive care drug by Novartis is specially designed for cancer patients that already have had other anti-cancer therapies.

Cancer Types Covered:

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Other Cancer Types

Supportive Care Types Covered:

  • Chemotherapy-induced Nausea & Vomiting (CINV) Management
  • Anaemia Management
  • Neutropenia Management
  • Bone Metastasis Management
  • Pain Management
  • Fatigue Management
  • Other Supportive Care Types

Drug Types Covered:

  • Anti-emetics
  • Erythropoiesis-stimulating Agents (ESAs)
  • Granulocyte Colony-stimulating Factors (G-CSFs)
  • Bisphosphonates
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Other Drug Types

Mode of Administrations Covered:

  • Oral Drugs
  • Injectable Drugs
  • Topical Drugs
  • Intravenous Drugs
  • Other Mode of Administrations

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Cancer Treatment Centers
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cancer Supportive Care Drugs Market, By Cancer Type

  • 5.1 Introduction
  • 5.2 Breast Cancer
  • 5.3 Lung Cancer
  • 5.4 Prostate Cancer
  • 5.5 Colorectal Cancer
  • 5.6 Other Cancer Types

6 Global Cancer Supportive Care Drugs Market, By Supportive Care Type

  • 6.1 Introduction
  • 6.2 Chemotherapy-induced Nausea & Vomiting (CINV) Management
  • 6.3 Anaemia Management
  • 6.4 Neutropenia Management
  • 6.5 Bone Metastasis Management
  • 6.6 Pain Management
  • 6.7 Fatigue Management
  • 6.8 Other Supportive Care Types

7 Global Cancer Supportive Care Drugs Market, By Drug Type

  • 7.1 Introduction
  • 7.2 Anti-emetics
  • 7.3 Erythropoiesis-stimulating Agents (ESAs)
  • 7.4 Granulocyte Colony-stimulating Factors (G-CSFs)
  • 7.5 Bisphosphonates
  • 7.6 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • 7.7 Corticosteroids
  • 7.8 Other Drug Types

8 Global Cancer Supportive Care Drugs Market, By Mode of Administration

  • 8.1 Introduction
  • 8.2 Oral Drugs
  • 8.3 Injectable Drugs
  • 8.4 Topical Drugs
  • 8.5 Intravenous Drugs
  • 8.6 Other Mode of Administrations

9 Global Cancer Supportive Care Drugs Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 Online Pharmacies
  • 9.5 Cancer Treatment Centers
  • 9.6 Other Distribution Channels

10 Global Cancer Supportive Care Drugs Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Amgen Inc.
  • 12.2 Johnson & Johnson
  • 12.3 Pfizer Inc.
  • 12.4 Novartis International AG
  • 12.5 Merck & Co. Inc.
  • 12.6 Teva Pharmaceutical Industries Limited
  • 12.7 F. Hoffmann-La Roche Limited
  • 12.8 Bayer AG
  • 12.9 Eli Lilly and Company
  • 12.10 AstraZeneca PLC
  • 12.11 Bristol Myers Squibb
  • 12.12 GlaxoSmithKline PLC
  • 12.13 Takeda Pharmaceutical Company Limited
  • 12.14 AbbVie Inc.
  • 12.15 Daiichi Sankyo Company

List of Tables

  • Table 1 Global Cancer Supportive Care Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Cancer Supportive Care Drugs Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 3 Global Cancer Supportive Care Drugs Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 4 Global Cancer Supportive Care Drugs Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 5 Global Cancer Supportive Care Drugs Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 6 Global Cancer Supportive Care Drugs Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 7 Global Cancer Supportive Care Drugs Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 8 Global Cancer Supportive Care Drugs Market Outlook, By Supportive Care Type (2021-2030) ($MN)
  • Table 9 Global Cancer Supportive Care Drugs Market Outlook, By Chemotherapy-induced Nausea & Vomiting (CINV) Management (2021-2030) ($MN)
  • Table 10 Global Cancer Supportive Care Drugs Market Outlook, By Anaemia Management (2021-2030) ($MN)
  • Table 11 Global Cancer Supportive Care Drugs Market Outlook, By Neutropenia Management (2021-2030) ($MN)
  • Table 12 Global Cancer Supportive Care Drugs Market Outlook, By Bone Metastasis Management (2021-2030) ($MN)
  • Table 13 Global Cancer Supportive Care Drugs Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 14 Global Cancer Supportive Care Drugs Market Outlook, By Fatigue Management (2021-2030) ($MN)
  • Table 15 Global Cancer Supportive Care Drugs Market Outlook, By Other Supportive Care Types (2021-2030) ($MN)
  • Table 16 Global Cancer Supportive Care Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 17 Global Cancer Supportive Care Drugs Market Outlook, By Anti-emetics (2021-2030) ($MN)
  • Table 18 Global Cancer Supportive Care Drugs Market Outlook, By Erythropoiesis-stimulating Agents (ESAs) (2021-2030) ($MN)
  • Table 19 Global Cancer Supportive Care Drugs Market Outlook, By Granulocyte Colony-stimulating Factors (G-CSFs) (2021-2030) ($MN)
  • Table 20 Global Cancer Supportive Care Drugs Market Outlook, By Bisphosphonates (2021-2030) ($MN)
  • Table 21 Global Cancer Supportive Care Drugs Market Outlook, By Nonsteroidal Anti-inflammatory Drugs (NSAIDs) (2021-2030) ($MN)
  • Table 22 Global Cancer Supportive Care Drugs Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 23 Global Cancer Supportive Care Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 24 Global Cancer Supportive Care Drugs Market Outlook, By Mode of Administration (2021-2030) ($MN)
  • Table 25 Global Cancer Supportive Care Drugs Market Outlook, By Oral Drugs (2021-2030) ($MN)
  • Table 26 Global Cancer Supportive Care Drugs Market Outlook, By Injectable Drugs (2021-2030) ($MN)
  • Table 27 Global Cancer Supportive Care Drugs Market Outlook, By Topical Drugs (2021-2030) ($MN)
  • Table 28 Global Cancer Supportive Care Drugs Market Outlook, By Intravenous Drugs (2021-2030) ($MN)
  • Table 29 Global Cancer Supportive Care Drugs Market Outlook, By Other Mode of Administrations (2021-2030) ($MN)
  • Table 30 Global Cancer Supportive Care Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 31 Global Cancer Supportive Care Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 32 Global Cancer Supportive Care Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 33 Global Cancer Supportive Care Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 34 Global Cancer Supportive Care Drugs Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
  • Table 35 Global Cancer Supportive Care Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.